Blackstone’s Autolus Therapeutics AUTL Stock Holding History
Bought
Maintained
Sold
Other funds holding AUTL
Blackstone's AUTL Position: Q2 2026 in Review
Blackstone held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 20,485,611 shares worth $32.8M. The position accounts for 0.08% of the portfolio, ranked #63.
Blackstone first reported a position in AUTL in Q4 2021 and has held it in 19 quarters since. The position peaked at $132M in Q4 2023. 83 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.
- Blackstone held 20,485,611 shares of Autolus Therapeutics worth $32.8M as of Q2 2026.
- Blackstone left its Autolus Therapeutics share count unchanged in Q2 2026.
- Autolus Therapeutics made up 0.08% of Blackstone's portfolio in Q2 2026, its #63 holding.
- Blackstone first reported a position in Autolus Therapeutics in Q4 2021 and has held it in 19 quarters since.
- Blackstone's Autolus Therapeutics position peaked at $132M in Q4 2023.
- 83 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.
Based on Blackstone's 13F filing for Q2 2026, filed 14 Aug 2026.